To gain insight into the efficacies of currently utilized CAR-T therapies and bispecific Abs, both of which engage T cells and MM cells through the binding of CD3 on T cells to the specific antigens on MM cells, such as BCMA [30, 31], GPRC5D [32, 33], and FcRH5 (also known as FcRL5) [34, 35], we examined their expression on CD34+ and CD34− MM cells from 4 NDMM patients. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.